Download this complimentary Expert Insights eBook today!
The COVID-19 pandemic has brought much attention to the medical utility of rapid point-of-care (POC) tests and lateral flow assays. Although these assays are easy to use and provide quick diagnostic results at the point-of-care, the prevalence of false-positive and false-negative results has been one of the main limitations in their development.
To understand and improve the sensitivity and detection of rapid POC tests, researchers need to obtain insights into the critical components of lateral flow assay development. These components include IVDR/regulatory approvals, analyte and sample preparation, antibody selection, and detection chemistries.
This Expert Insights publication provides an overview of these components of lateral flow assay development. The studies and expert interview featured in this publication are intended to educate researchers on important considerations and strategies to enhance the design and development of rapid POC tests.
What you will learn:
- Key components of POC tests and lateral flow assay development
- Considerations for lateral flow assay design and strategies to enhance the sensitivity of your rapid POC tests
- Latest advancements in virus detection by rapid POC tests, particularly SARS-CoV-2
More Information
- In vitro Diagnostics for Screening the Blood Supply: The New European Regulation for IVD and the WHO IVD Prequalification Programme
- Competing Policy Windows in Biotechnology: The FDA, the 21st Century Cures Act, and Laboratory-Developed Tests
- Recent Applications of Paper-based Point-of-Care Devices for Biomarker Detection
- Diagnostic Ability of Salivary Matrix Metalloproteinase-9 Lateral Flow Test Point-of-Care Test for Periodontitis
- Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta‐analysis
- Rapid diagnostic testing for SARS‐CoV‐2: Validation and comparison of three point‐of‐care antibody tests
- An Overview for the Nanoparticles-Based Quantitative Lateral Flow Assay
- Alkaline Phosphatase-based Electrochemical Analysis for Point-of-Care Testing
- An HRP‐labeled Lateral Flow Immunoassay for Rapid Simultaneous Detection and Differentiation of Influenza A and B viruses
- Recent Advances and Clinical Application in Point‐of‐Care Testing of SARS‐CoV‐2
Brought to you by
Sponsored by
